Synapse - Department of Medicine

Results (39622)

Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study

Meeting Abstract

Shore, N. D.; Sieber, P. R.; Gleave, M.; De Giorgi, U.; Mehlhaff, B. A.; Danila, D. C.; Dunshee, C.; Lallas, C. D.; Pliskin, M.; Tang, Y.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study

Meeting Abstract

Rathkopf, D. E.; Roubaud, G.; Chi, K. N.; Efstathiou, E.; Attard, G.; Olmos, D.; Small, E. J.; Saad, M.; Castro, E.; Kim, W.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D. W.; Lakhani, N. J.; Hawley, J. E.; Aparicio, A.; Narayan, V.; Srinivas, S.; Runcie, K.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations

Meeting Abstract

Zalcberg, J. R.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Reichmann, W.; Sprott, K.; Cox, P.; Sherman, M. L.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Genomic profiling of bladder cancer in waterpipe and cigarette smokers: Implications for carcinogenicity and genetic landscape

Meeting Abstract

Shamseddine, A.; Abbas, N.; Chatila, W. K.; Walch, H. S.; Eichholz, J.; Schultz, N.; Solit, D. B.; Charafeddine, M.; Al Darazi, M.; Abou-Alfa, G. K.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study

Meeting Abstract

Voss, M. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update

Meeting Abstract

Segal, N. H.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Han, H.; Casey, K. A.; Li, S.; Ganguly, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)

Meeting Abstract

Janjigian, Y. Y.; Raoufmoghaddam, S.; Sztachelska, M.; Winter, M.; Das, S.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma

Meeting Abstract

Dayyani, F.; Baretti, M.; Lee, S. S.; He, A. R.; Kim, R. D.; Lin, B. S. L.; Enzler, T.; Al Hallak, M. N.; Ulahannan, S. V.; Davis, S. L.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2

Meeting Abstract

Deming, D. A.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.; Iyer, G.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save